Opinion

The Cultural Deficit in the Pharma Industry in the Era of COVID-19

September 10, 2020

Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?

Extension of Medicare is the Affordable Solution to Current Healthcare Problems

August 24, 2020

COVID-19 has only magnified well known flaws of our healthcare system. An extension of Medicare is the affordable solution, writes Bruno Delagneau, and pharma needs to start planning for this to minimize its impact on US revenues.

Pricing, Innovation, and a Pound of Flesh

August 10, 2020

How “Contractual Genericization” could revitalize pharma and reframe the public conversation.

Will the Industry Rise to the Occasion?

July 09, 2020

Gilead's pricing of COVID drug remdesivir is a reminder of pharma's tenuous path forward as it seeks a more holistic image makeover.

Vaccine “Hesitancy” Threatens COVID Immunization Efforts

June 01, 2020

While scientists are striving to discover and produce safe and effective vaccines to halt the coronovirus outbreak, anti-vacciners are revving up misinformation campaigns.

Master the Science of Success

May 01, 2020

Welcome to the new look and branding of Pharmaceutical Executive-reimagined to better reflect you, our audience, and expand on the content you've long trusted us to deliver.

A Bold Deal Could Help Trump Administration End HIV in America

August 13, 2019

The US could theoretically treat every single American living with HIV without spending an extra dollar on drugs. And President Trump can broker a deal to do it, write Anil Soni and Ya’ir Aizenman.